High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Polymeric micelle formulation of an immune modulator improves survival in a highly aggressive model of non–small cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequently employed combinations are 1) a combination of several chemotherapies for killing cancer cells, 2) a combination of chemotherapy with additional agents, such as tumor microenvironment modifiers, or more recently 3) a combination of immunotherapy with anticancer agents [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The latest study highlighted that even the best combinations of the chemotherapeutic agents determined in vitro as having the most potent and highly synergistic effect against non-small cell lung cancer (NSCLC) cells may not be effective against the in vivo tumor even at the MTD of those combinations [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, resiquimod, an imidazoquinoline TLR 7/8 agonist, solubilized in POx block copolymer (PMeOx-b-PBuOx-b-PMeOx) micelles had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti-PD1 immune checkpoint blockade therapy as well as platinum-based chemotherapy, which is the mainstay of treatment for NSCLC.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Investigation of the in vivo immune status following resiquimod in polymeric micelles treatment showed that resiquimod-based stimulation of antigen-presenting cells in the tumor microenvironment resulted in the mobilization of anti-tumor CD8+ immune response [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Certain cancers overexpress PD-L1 to benefit from PD-1/PD-L1 axis–mediated suppression of adaptive immunity (3).”
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“4 of 12 of Chou and Talalay, which states that a CI value of less than 1 represents synergy, whereas a CI value greater than 1 indicates antagonism (24).”
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“IL-6 signaling is again pivotal to the differentiation of T and B cells (30).”
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“However, the initial response to cisplatin is often short-lived because of the development of drug resistance (17).”
Non-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942 · cited 2×
“Nevertheless, the benefits of such interventions are often transient due to the development of chemoresistance, which primarily stems from tumor-host cell interactions (1).”
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 1×
“(55) showed both IL-1 and IL-6 (implicated as a key driver of cytokine storm) were involved in the pathogenesis of cytokine storm in a humanized mouse model of leukemia, and because IL-1 signaling preceded IL-6, the blockade of IL-1 receptor was shown to successfully overcome the toxicities associated with the syndrom…”
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Yang, J., Zhang, L., Yu, C., Yang, X.-F., & Wang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-1 · Cited by 1,099 · cited 1×
“Ly6C+ monocytes are prone to differentiate into inflammatory macrophages and secrete TH1 cytokines that activate adaptive immune response (38).”
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Self-citationDecoding Toll-like receptors: Recent insights and perspectives in innate immunity
Kawai, T., Ikegawa, M., Ori, D., & Akira, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.004 · Cited by 528
Bhagchandani, S., Johnson, J. A., & Irvine, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.013 · Cited by 188
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Sun, H., Li, Y., Zhang, P., Xing, H., Zhao, S. Q., Song, Y., Wan, D., & Yu, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00436-7 · Cited by 166
“Another study showed that R848-based stimulation of APCs in the tumor microenvironment resulted in the mobilization of an antitumor CD8+ immune response for treating metastatic NSCLC [70].”
BackgroundInfluentialZahoranová, A., & Luxenhofer, R. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001382 · Cited by 119
The future of poly(2-oxazoline)s
Hoogenboom, R. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111521 · Cited by 113
New Advances in Biomedical Application of Polymeric Micelles
Figueiras, A., Domingues, C., Jarak, I., Santos, A. I., Parra, A., Pais, A. A. C. C., Alvarez‐Lorenzo, C., Concheiro, Á., Kabanov, A. V., Cabral, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081700 · Cited by 111
Self-citationHarnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy
Lee, D., Huntoon, K. M., Wang, Y., Jiang, W., & Kim, B. Y. S. (2021) · Advanced Materials · doi:10.1002/adma.202007576 · Cited by 74
Lim, C., Ramsey, J. D., Hwang, D., Teixeira, S. C. M., Poon, C., Strauss, J. D., Rosen, E. P., Sokolsky‐Papkov, M., & Kabanov, A. V. (2021) · Small · doi:10.1002/smll.202103552 · Cited by 76
Self-citationGu, J., Zhao, G., Yu, J., Xu, P., Yan, J., Jin, Z., Chen, S., Wang, Y., Zhang, L. W., & Wang, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01561-z · Cited by 65
Bhagchandani, S. H., Vohidov, F., Milling, L. E., Tong, Y. E., Brown, C. M., Ramseier, M. L., Liu, B., Fessenden, T. B., Nguyen, H. V. ‐., Kiel, G. R., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg2239 · Cited by 60
“Nonlinear dose-toxicity relationships confound MTD studies for IMDs such as R848 and are thus difficult to precisely define ( 58 ).”
The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
Huang, L., Ge, X., Liu, Y., Li, H., & Zhang, Z. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061228 · Cited by 61
“poly(2-oxazoline) (POx)–based nanomicellar TLR7/8 R848 anti-PD-1 intravenous 344SQ lung adenocarcinoma (LUAD) [89]”
Jana, S., & Hoogenboom, R. (2022) · Polymer International · doi:10.1002/pi.6426 · Cited by 57
Polymeric Micelles in Cancer Immunotherapy
Wan, Z., Zheng, R., Moharil, P., Liu, Y., Chen, J., Sun, R., Song, X., & Ao, Q. (2021) · Molecules · doi:10.3390/molecules26051220 · Cited by 53
Hoffmann, C., Noël, F., Grandclaudon, M., Massenet-Regad, L., Michea, P., Sirven, P., Faucheux, L., Surun, A., Lantz, O. J., Bohec, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29516-w · Cited by 68
Tumor Microenvironment Remodeling‐Mediated Sequential Drug Delivery Potentiates Treatment Efficacy
Xu, Y., Lv, J., Liu, F., Wang, J., Liu, Y., Kong, C., Li, Y., Shen, N., Gu, Z., Tang, Z., et al. (2024) · Advanced Materials · doi:10.1002/adma.202312493 · Cited by 50
Engineering biomaterials to prevent post-operative infection and fibrosis
Josyula, A., Parikh, K. S., Pitha, I., & Ensign, L. M. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00955-0 · Cited by 48
Hwang, D., Vinod, N., Skoczen, S. L., Ramsey, J. D., Snapp, K. S., Montgomery, S. A., Wang, M., Lim, C., Frank, J. E., Sokolsky‐Papkov, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121140 · Cited by 45
Self-citationLugani, S., Halabi, E. A., Oh, J., Köhler, R. H., Peterson, H. M., Breakefield, X. O., Chiocca, E. A., Miller, M. A., Garris, C., & Weissleder, R. (2022) · Advanced Materials · doi:10.1002/adma.202208782 · Cited by 46
Mathew, A. A., Zakkariya, Z. T., Ashokan, A., Manohar, M., Pavithran, K., Nair, S. V., & Koyakutty, M. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110129 · Cited by 48
Varshney, D., Qiu, S. Y., Graf, T. P., & McHugh, K. J. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00620-x · Cited by 48
Kang, Y., Flores, L., Ngai, H. W., Cornejo, Y. R., Haber, T., McDonald, M., Moreira, D., Gonzaga, J. M., Abidi, W., Zhang, Y., et al. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00139 · Cited by 36
Anfray, C., Fernández‐Varela, C., Ummarino, A., Maeda, A., Sironi, M., Gandoy, S., Brea, J. M., Loza, M. I., León, S., Calvo, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1334800 · Cited by 31
Highway to Success—Developing Advanced Polymer Therapeutics
Ashford, M. B., England, R., & Akhtar, N. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000285 · Cited by 35
Slezak, A. J., Mansurov, A., Raczy, M. M., Chang, K., Alpar, A. T., Lauterbach, A. L., Wallace, R. P., Weathered, R. K., Medellin, J. E. G., Battistella, C., et al. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00704 · Cited by 30
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases
Aldarondo, D., & Wayne, E. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114116 · Cited by 36
Self-citationA dual macrophage polarizer conjugate for synergistic melanoma therapy
Sallam, M. A., Shields, C. W., Prakash, S., Kim, J., Pan, D. C., & Mitragotri, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.033 · Cited by 24
Torres, F., Leon, S., Ummarino, A., Redín, E., Allavena, P., Serrano, D., Anfray, C., & Calvo, A. (2022) · Biomedicines · doi:10.3390/biomedicines10071590 · Cited by 24
“Other studies have shown antitumor and antimetastatic activity using resiquimod-encapsulated poly(2-oxazoline) NPs in an orthotopic model of NSCLC, an effect that was mediated by Ly6C+ monocytes and CD8+ T lymphocytes [59].”
BackgroundWu, J., Li, J.-X., Shu, N., Duan, Q.-J., Tong, Q., Zhang, J., Huang, Y., Yang, S., Zhao, Z., & Du, J. (2021) · Nano Research · doi:10.1007/s12274-021-3510-0 · Cited by 23
Microbial-Derived Toll-like Receptor Agonism in Cancer Treatment and Progression
Giurini, E. F., Madonna, M. B., Zloza, A., & Gupta, K. H. (2022) · Cancers · doi:10.3390/cancers14122923 · Cited by 22
Wang, B., Cui, H., Kiessling, F. M., Lammers, T., Baumjohann, D., & Shi, Y. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.028 · Cited by 20
Liotti, F., Marotta, M., Sorriento, D., Pone, E., Morra, F., Melillo, R. M., & Prevete, N. (2021) · Cancers · doi:10.3390/cancers13040740 · Cited by 16
Haider, M. S., Mahato, A. K., Котлярова, А. А., Forster, S., Böttcher, B., Stahlhut, P., Sidorova, Y. A., & Luxenhofer, R. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c00761 · Cited by 14
Wang, D., Cao, Y., Meng, M., Qiu, J. F., Ni, C., Guo, X., Li, Y., Liu, S., Yu, J. L., Guo, M., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002621 · Cited by 15
“Lung adenocarcinoma is characterized of strong metastatic capacity, thus is associated with poor prognosis and becomes one of the leading causes of mortality in cancer patients [1].”
Facile one-pot synthesis of 2-oxazoline
Zhu, J., Zhou, M., Jiang, W., Zhou, Y., Song, G., & Liu, R. (2022) · Tetrahedron Letters · doi:10.1016/j.tetlet.2022.153637 · Cited by 10
Nanomedicine approaches for medulloblastoma therapy
Lim, C., Koo, J., & Oh, K. T. (2022) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00597-5 · Cited by 11
“Although Cmax decreased, the nano-formulation could increase the drug area under the curve (AUC) in blood, enabling high-dose therapy (Hwang et al. 2021; Lim et al. 2022a, b; Vinod et al. 2020; Wan et al. 2019).”
BackgroundWang, Y., Qiu, W., Chen, J., Meng, W., Zhao, R., Lin, W., Mei, P., Diao, M., Han, X., & Liao, Y. (2023) · International Journal of Cancer · doi:10.1002/ijc.34563 · Cited by 14
“H1975 cells (2 10(6)) were infected with the negative control oeRNA luciferase virus or the oeESR2 luciferase virus and then injected into the left lung of these mice (in 50 μL of the 1:1 mix of PBS and Matrigel [BD Biosciences]).(31) The mice were divided into three groups (1: Control; 2: oeERβ; 3: oeERβ + A 205804).”
MethodPodevyn, A., Guyse, J. F. R. V., Bouten, P. J. M., van Hest, J. C. M., & Hoogenboom, R. (2025) · Macromolecules · doi:10.1021/acs.macromol.4c02523 · Cited by 9
Interpolyelectrolyte Complexes as an Emerging Technology for Pharmaceutical Delivery of Polypeptides
Fay, J. M., & Kabanov, A. V. (2022) · Reviews and Advances in Chemistry · doi:10.1134/s2634827622600177 · Cited by 11
Self-citationVinod, N., Hwang, D., Azam, S. H., Swearingen, A. E. D. V., Wayne, E. C., Fussell, S. C., Sokolsky‐Papkov, M., Pecot, C. V., & Kabanov, A. V. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3959 · Cited by 8
“The original work (Vinod et al., 2020) was funded by the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer (U54CA198999, Carolina Center of Cancer Nanotechnology Excellence).”
MethodSelf-citationWang, X., Lu, Z., Zeng, Z., Cai, J., Xu, P., & Liu, A. (2021) · Medicine · doi:10.1097/md.0000000000027279 · Cited by 11
Haider, M. S., & Luxenhofer, R. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-s8xc3 · Cited by 8
Humphries, J., Warne, N. M., Feeney, O. M., Thurecht, K. J., & Kempe, K. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114838 · Cited by 11
Wang, Y., Yu, T., Chen, J., Zhao, R., Diao, M., Mei, P., He, S., Qiu, W., Ye, G., Jiang, L., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11415-y · Cited by 7
“The LLC cells (1 × 10 6 ) expressing firefly luciferase were injected directly into the left lung (in 50 µL of 1:1 mix of PBS and Matrigel (BD Biosci-ences)) three days after surgery [37].”
MethodHe, K., Gong, G., Liang, E., Lv, Y., Lin, S., & Xu, J. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101844 · Cited by 5
“Resistant phenotypes are strongly correlated with drug resistance genes, which remains a major cause of chemotherapy failure [48,49].”
BackgroundVaranaraja, Z., Terracciano, R., Hollingsworth, N., Green, R., Beament, J., & Becer, C. R. (2024) · Macromolecules · doi:10.1021/acs.macromol.4c00843 · Cited by 5
Halupczok, S., Pfister, M., Ringhand, A., Fetsch, C., Cubukova, A., Appelt‐Menzel, A., & Luxenhofer, R. (2020) · Polymer Chemistry · doi:10.1039/d0py01258k · Cited by 4
PEG-Free Polyion Complex Nanocarriers for Brain-Derived Neurotrophic Factor
Fay, J. M., Lim, C., Finkelstein, A., Batrakova, E. V., & Kabanov, A. V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071391 · Cited by 4
Self-citationPotential role of lactylation in intrinsic immune pathways in lung cancer
Huang, M., Jin, Y., Zhao, D., & Liu, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1533493 · Cited by 7
Salem, A., Attia, S., El‐Ghlban, S., Montaser, A. S., Abdelhameed, M. F., Helmy, M. W., & Attia, M. F. (2025) · Macromolecular Bioscience · doi:10.1002/mabi.202500388 · Cited by 4
“Analysis was performed following previously established methods [29].”
Tambunlertchai, S., Geary, S. M., Naguib, Y. W., & Salem, A. K. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00824-3 · Cited by 3
Vinod, N., Hwang, D., Azam, S. H., Swearingen, A. E. D. V., Wayne, E. C., Fussell, S. C., Sokolsky‐Papkov, M., Pecot, C. V., & Kabanov, A. V. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3953 · Cited by 2
Self-citationDelivery strategies for cancer vaccines and immunoadjuvants
Graham-Gurysh, E. G., Carpenter, B. W., Beck, W. A., Varma, D. M., Vincent, B. G., Bachelder, E. M., & Ainslie, K. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00014-2 · Cited by 2
Haider, M. S., Mahato, A. K., Котлярова, А. А., Forster, S., Böttcher, B., Stahlhut, P., Sidorova, Y. A., & Luxenhofer, R. (2021) · ChemRxiv · doi:10.33774/chemrxiv-2021-ffsvz · Cited by 1
Polymeric micelles as delivery systems for anticancer immunotherapy
Parayath, N. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89868-3.00004-5
Salem, A., Attia, S., El‐Ghlban, S., Montaser, A. S., Abdelhameed, M. F., Helmy, M. W., & Attia, M. F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.04.647265
Gu, J., Zhao, G., Yu, J., Xu, P., Yan, J., Jin, Z., Chen, S., Wang, Y., Zhang, L. W., & Wang, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20479559
He, Y., & Yeo, Y. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70052
Systems analysis of intercellular communication in the tumor microenvironment
Massenet-Regad, L. (2023) · theses.fr (ABES) · doi:10.70675/909b8153z00efz42f7za922z6b476829dbf2
McSwain, L., Kim, K., Hwang, D., Lim, C., Winham, C. L., Jacques, J., Jonus, H. C., Rosen, E. P., Pradhan, A., Kasturi, S. P., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.07.714454
Self-citationHigh-Capacity Dexamethasone-Loaded Poly(2-Oxazoline) Micelles for Ocular Surface Applications
Verma-Fuehring, R., Wiesler, M., Obeysekara, U., Flegler, V. J., Böttcher, B., Kampik, D., Hillenkamp, J., & Haider, M. S. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c01227
Jana, S., & Hoogenboom, R. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115975
Haider, M. S., & Luxenhofer, R. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.6c01970
Metadata
- Authors
- Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.
- Corresponding author
- Pecot, Chad V.
- Kabanov, Alexander V.
- ORCID
- Venue
- Science Advances
- Published
- 2020-06-17
- Volume
- 6
- Issue
- 25
- Pages
- eaba5542-eaba5542
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7299629
- OpenAlex
- W3036026766
- Cited by
- 63
- References
- 64
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 20 · 2021: 18 · 2020: 2
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by-nc)
- UNC Libraries
- Funders
- National Institutes of Health (5U54CA198999-05)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- poly(2-oxazoline), resiquimod, TLR7/8 agonist, lung adenocarcinoma, metastatic non-small cell lung cancer, drug formulation, survival, cancer immunotherapy
- MeSH terms
- Adenocarcinoma of Lung, Adjuvants, Immunologic, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Oxazoles, Toll-Like Receptor 7, Toll-Like Receptor 8, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.